What Eli Lilly Doubters Got Wrong
If you had been weighing Eli Lilly in October 2025, the argument was not just about obesity excitement but whether aging and chronic disease trends could really support the rich expectations already baked into the stock. For Eli Lilly shareholders, the return over the past year was 55.2%, including dividends. If you were deciding back then whether to buy, hold, or wait, an important question was which mattered more: drug pricing risks or the scale of the GLP-1 opportunity?
The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.
The easy part of this move is behind Eli Lilly. Zero in on 27 high quality undervalued stocks for companies trading below our estimates.
The Argument Eli Lilly Investors Were Really Having
The shares cost US$821 at the start of the period, so any decision on Eli Lilly hinged on whether that quote already captured the full obesity and aging story or still left room for upside.
On the bullish side, the Fair Value was set at US$1,190, built on the idea that aging and obesity trends would expand chronic disease markets and that small molecule GLP-1s like orforglipron could open up primary care and global obesity treatment.
The bearish Narrative pointed to a Fair Value of US$650, stressing U.S. drug pricing reforms and pricing parity efforts as key threats to future profitability for Eli Lilly, especially for its high profile diabetes and obesity portfolio.
What The Evidence Did To The Eli Lilly Argument
Foundayo’s approval and rapid uptake, along with retatrutide’s strong Phase 3 data, leaned toward the bullish Eli Lilly view that GLP-1 science and new formats could widen obesity treatment. Reported results added another piece. Revenue reached US$15,558m in Q2 2025 and US$22,974m in Q2 2026, and net income also rose, although net margin slipped from 36.4% to 30.9%. The evidence cut both ways.
The lesson travels easily. When a story hinges on pricing power versus volume, do not just track sales. Compare revenue, absolute profit and net margin, and test that trio against the original pricing and scale assumptions.
What Eli Lilly’s Price Already Assumes Today
Eli Lilly now trades at US$1,273 after a 55.2% gain over the past year, while this Narrative’s Fair Value sits below that level. The gap reflects concern that the current quote already bakes in very strong execution across obesity, diabetes and newer areas like oncology and neuroscience.
At today’s price, you are effectively assuming Eli Lilly can turn its GLP-1 manufacturing build out and cardiometabolic pipeline into long lasting worldwide volume gains. How does the selected Narrative’s focus on pricing pressure, legal risk and reimbursement limits affect that assumption?
"The main factor that needs to go right is that Eli Lilly converts its large incretin manufacturing build out, obesity access programs and cardiometabolic pipeline into durable worldwide volume growth that more than offsets pricing pressure and any legal or safety overhangs."
That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for
Where Eli Lilly’s Story Echoes
Eli Lilly spotlights obesity and chronic disease. You could stop there.
Or you could ask how similar science is being pushed elsewhere, especially where obesity drugs and cancer agents both matter.
One large group is pouring effort into a fresh obesity candidate and an expanded oncology pipeline built around targeted antibody therapies.
The aim is to turn clinical programs into revenue beyond older treatments, using savings to back more launches.
If that shift holds, the mix of earnings, cash use and investor attention might look very different from today.
That argument has a Narrative and a number behind it. → See the company one Narrative values 20% above its price
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com